Upcoming strategies for the treatment of metastatic melanoma

Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 Inhibitor

(2015) Jeffrey R. Tseng et al.   NEOPLASIA

BRAF as a Target for Cancer Therapy

(2012) Rodrigo Dienstmann et al.   Anti-Cancer Agents in Medicinal Chemistry

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

(2011) Y. Kong et al.   CLINICAL CANCER RESEARCH

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib cardiac toxicity: Should we still be concerned?

(2011) Ehab Atallah   LEUKEMIA RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of Melanoma

(2011) Darrell S. Rigel   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Molecular Therapy in Melanoma

(2010) Igor Puzanov et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy

(2010) Kim A. Margolin et al.   SEMINARS IN ONCOLOGY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells

(2008) Konstantinos G. Lasithiotakis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

(2008) Jose Lutzky et al.   Pigment Cell & Melanoma Research